Skip to main content
Premium Trial:

Request an Annual Quote

Silico Insights Pushes Ashni Partnership Forward into Drug Discovery

Premium

Silico Insights is looking to build on intellectual property it recently gained through its year-long partnership with Ashni Naturaceuticals.

The research collaboration generated several patents in the fields of pathway elucidation, informatics, and gene function leading to estrogen-induced inflammation.

Nandan Padukone, president of Silico Insights, told BioInform that the companies decided that Silico Insights had a better model for capitalizing on the intellectual property generated through the Ashni partnership.

As a result, Dinesh Patel, Ashni co-founder and CEO, will now serve as chairman and CEO of Silico Insights to help launch the effort. Patel will retain his position at Ashni of Salt Lake City and perform his duties at Silico Insights on a consulting basis.

John Babish, who headed research at Ashni, has also joined Silico Insights as vice president of research.

Silico Insights has full rights to access and use the IP developed through the partnership. The technology has been used to extend the i-Sight platform to identify inflammation-based pathways.

The company plans to license the pathways on an R&D alliance basis. Padukone said drug development companies could use the platform to either screen their libraries of drug compounds or could work with Silico Insights to co-develop new pathways.

— BT

Filed under

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.